Fenfluramine low dose - Zogenix

Drug Profile

Fenfluramine low dose - Zogenix

Alternative Names: Brabafen; Fintepla; Low-dose fenfluramine; ZX-008

Latest Information Update: 25 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Brabant Pharma
  • Developer Brabant Pharma; Katholieke Universiteit Leuven; University of Antwerp; Zogenix
  • Class Amphetamines; Anorectics; Antiepileptic drugs; Small molecules
  • Mechanism of Action Serotonin receptor agonists; Sigma-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lennox-Gastaut syndrome; Dravet syndrome
  • New Molecular Entity No

Highest Development Phases

  • Phase III Dravet syndrome
  • Phase II Lennox-Gastaut syndrome
  • Preclinical Epilepsy

Most Recent Events

  • 22 Jun 2017 Fenfluramine low dose - Zogenix receives Orphan Drug status for Lennox-Gastaut syndrome in USA
  • 22 May 2017 Pharmacodynamics data from a preclinical trial in Dravet syndrome released by Zogenix
  • 04 May 2017 Zogenix plans a phase III trial in Lennox-Gastaut syndrome in the second half of 2017. First patient from this planned trial will be enrolled in fourth quarter of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top